FY2029 Earnings Forecast for ACRV Issued By HC Wainwright

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) – Equities research analysts at HC Wainwright issued their FY2029 earnings estimates for Acrivon Therapeutics in a report issued on Wednesday, March 26th. HC Wainwright analyst E. Bodnar anticipates that the company will earn ($1.25) per share for the year. HC Wainwright has a “Buy” rating and a $19.00 price objective on the stock. The consensus estimate for Acrivon Therapeutics’ current full-year earnings is ($2.49) per share.

Acrivon Therapeutics (NASDAQ:ACRV) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.06.

A number of other research firms also recently issued reports on ACRV. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Acrivon Therapeutics in a report on Wednesday. KeyCorp started coverage on shares of Acrivon Therapeutics in a research note on Friday, January 31st. They issued an “overweight” rating for the company. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, Acrivon Therapeutics presently has a consensus rating of “Buy” and an average price target of $23.17.

Acrivon Therapeutics Stock Performance

ACRV stock opened at $2.52 on Thursday. The company’s fifty day moving average price is $5.42 and its 200-day moving average price is $6.57. Acrivon Therapeutics has a one year low of $2.44 and a one year high of $11.90. The company has a market capitalization of $78.46 million, a PE ratio of -0.93 and a beta of 0.85.

Institutional Investors Weigh In On Acrivon Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in ACRV. Wealthedge Investment Advisors LLC acquired a new stake in Acrivon Therapeutics during the 4th quarter worth about $65,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Acrivon Therapeutics by 29.7% during the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 102,784 shares of the company’s stock worth $619,000 after acquiring an additional 23,535 shares during the period. Corton Capital Inc. purchased a new position in Acrivon Therapeutics during the fourth quarter valued at approximately $73,000. Acorn Capital Advisors LLC acquired a new position in Acrivon Therapeutics in the fourth quarter valued at approximately $2,440,000. Finally, Northern Trust Corp boosted its position in Acrivon Therapeutics by 11.3% in the 4th quarter. Northern Trust Corp now owns 117,323 shares of the company’s stock worth $706,000 after purchasing an additional 11,925 shares in the last quarter. 71.62% of the stock is currently owned by institutional investors and hedge funds.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.